
Computational biologist | Cancer researcher. Ph.D. @astar_gis Postdoc @UHN. Early drug development and biomarker discovery @RocheCanada. Now @arteraAI
Toronto, Ontario
Joined May 2012
- Tweets724
- Following833
- Followers325
- Likes3.7K
Pinned Tweet
I want to see models built on mechanistic biological data. There is abundant experimental data and literature which has not been consolidated to build a well informed updated picture of the human cell 1/
Aditi Qamra retweeted
Time for the biggest drop of the week: auto-optimizations of eleven bioinformatics packages, focusing on read alignment. Each auto-optimization includes: a new unit test suite, the optimizations stacked on top, and a list of issues found during the validation.
I regret not getting any wetlab experience during my PhD. I never asked since my work was focused on computational methods. But knowing practically how high quality biological data is generated than just theoretically is invaluable esp now
42
Love this. Also to my previous tweet, the right data is where its at
>be dr. fei-fei li
>born in beijing, raised in chengdu
>dad moves to new jersey, follow at age 16
>speak almost no english
>parents open a dry cleaner
>work the counter on weekends
>get into princeton on a full scholarship
>study physics, because why not
>caltech phd
>everyone in AI is obsessed with algorithms
>bet on data instead
>"this will never scale" they say
>do it anyway
>get 14 million images hand-labeled
>a team from toronto trains a convnet on it in 2012
>error rate falls off a cliff
>deep learning era begins
>become stanford professor
>become google cloud chief scientist
>found stanford HAI
>press starts calling you the godmother of AI
>2024, most of the field is racing on language
>you say the next frontier is spatial intelligence
>co-found World Labs in 2024
>ship Atlas in 2026, a model that turns a few photos into a whole 3D world
1
61
It is unsurprising yet disappointing again that the pay range for scientist role responsible for identifying the right data has a much lower compensation upper cap compared to other technical roles. (Im aware that none of these salaries is to sneeze at)
D. E. Shaw Research AI/ML Roles Applications are now open!
13 roles spanning LLM research, agentic AI, drug discovery & infrastructure with transparent salary ranges from $115K to $1M base.
We're hiring researchers, engineers and scientists for hybrid roles in NYC, Durham or Pittsburgh. Selected candidates get variable comp (sign-on + year-end bonuses), relocation/immigration assistance and access to cutting-edge DESRES infrastructure.
Apply at the link here: deshawresearch.com/current-o…
Applications reviewed on rolling basis • Hybrid work
40
First time im reading a piece from an AI startup in healthcare that wasn't fluff
statnews.com/2026/08/26/biot…
3
64
Switched from comp bio to early drug discovery to build DP biomarkers.Common thread trying to find therapies for solid tumors.There is some sense of loss but learning new things,thinking laterally & working on projects w/ real impact has been far more fruitful than chasing grants
More people should switch fields mid-career. Publishing metric nonsense disincentives it more than is optimal for cross-pollination of ideas. It’s also much faster now that we can learn with AI! I’m having so much fun in infectious disease modeling and grateful for my colleagues.
2
134
Aditi Qamra retweeted
It indeed feels like the entire "AI×bio" industry is under a massive illusion about the hurdles of drug development.
I wonder how long people will continue raising billions on the basis of "we'll run AI on all scientific literature and multi-omics data, and we'll cure all disease in 10 years"
This is really a great piece.
In certain tech circles, it has become low-status to suggest that AGI won't automatically solve everything. I think models will continue to get smarter, but intelligence is often not the main bottleneck to physical world change.
More below 👇
writingruxandrabio.com/p/int…
Some points the article makes:
1. Intelligence is often not the main bottleneck
Increasingly, when I talk to people at AI labs, I keep hearing the same thing: that working on regulatory barriers to the diffusion of medical innovation is a waste of my time. AGI will solve all of that, they assure me, with the pitying look one might give a naive hamster awaiting its slaughter. I think they're wrong.
We've had the technology to build better housing for decades, yet it's more expensive than ever: this is because housing is a question of political will, not just capability. Something similar goes for medicine.
2. This is just a microcosm of a broader problem: a dismisal of institutional and cultural barriers, as well as the mundane and the human.
The regulatory barriers to AI diffusion in medicine is just one example of the kind of stuff that tends to be dismissed by the AGI-pilled people. I think in general, there is an underweighting of cultural and institutional shaped problems, as well as of the boring and mundane. Maybe this has to do with the "totalizing' feeling of being close to reaching the AGI-God: It becomes hard to care about other things.
But to me, problems like a decline in reading or the slop-ification of our minds due to these technologies are equally important. They do not seem to be seen as equally serious.
3. This has become a monoculture.
Certain SF tech circles (not everyone) have hardened into something close to a monoculture, where it's now genuinely low-status to suggest AGI might not be wholly transformative on its own.
The people who were early and right about AI made fortunes. Being right about this one big thing has created a sort of "halo effect" where many think they're right about everything. To question the most extreme claims about the effects on the real world often means you will be marked as dim, low-IQ, insufficiently "AGI-pilled." This often results in self-censorship. Other very smart tech people privately acknowledge the bottlenecks to real-world diffusion, but do not really talk about it.
Because the outside world has long been skeptical of AI (and continues to be), many in these circles have come to see themselves as dissenters. But I think AGI-maximalism is the safe and status-conferring view within their circles.
4. The real world has many barriers to progress -- more detail.
The "real world" has many barriers to diffusion that those who think intelligence is all that matters seem to ignore. I remember a Progress Conference in 2023 where the economist Tyler Cowen made exactly this argument to a room full of AGI-pilled attendees, many of whom were frankly incredulous.
The capabilities, he suggested, would arrive faster than the changes they were meant to produce; GDP growth would disappoint relative to the hype, and there would be no massive job displacement. So far, the data seem to bear him out.
I can speak about my own area, which is medical progress, which is often bottlenecked by institutional and regulatory or policy barriers and also by the sheer difficulty of producing experimental biological data and the inherent limits of biology.
One example, beyond my usual clinical trials points: our patent system rewards novel chemical matter much more than novel biology (finding new targets). This means whoever validates a new target bears the risk but finds it hard to capture the reward. The result is "target herding": a lot of drugs against the same de-risked pathways, meaning a lot of biological space goes underexplored.
Some of best-funded AI-bio companies (Chai Discovery, Isomorphic Labs) target molecule optimization, so the tractable part, not the frontier of finding new targets. It turns out even AI companies respond to legal and economic incentives!
Does this matter?
I think so...
We fixate on AGI gods, while more mundane problems pile up unattended. The social fabric is fraying in plain sight. More and more young adults cannot afford a house or sustain a relationship. People pour their youth into gambling apps, some of them now made more powerful by the very AI we keep discussing. People are de-skilling as they hand more thinking to machines.
Every one of these problems needs people working on it. Being in the thrall of digital deities that will magically dissolve all our problems pulls attention away from the simpler, more human troubles that are already here.
Note: I want to mention there was an earlier version of this X post that got a lot of reactions. I deleted it, because it became quite controversial and it was interfering with my work. One common rebuttal was that I am "making up a person to be mad at".
I have modified my X post now to capture more of the nuance that I hope is found in the original article. For example, not everyone in SF thinks this and my new post makes that more clear. The X post is a summary though and I encourage people to read the whole article. This is also a way to start a conversation, not a definitive statement.
My mum, maternal aunts and grandma all have AMD. High prob I will too. a-VEGF injections did not prevent their vision loss. This gives me a lot of hope
Big news today. Science's PRIMA visual prosthesis, our retinal implant for macular degeneration, has received its CE mark, which means marketing approval in Europe. This is a huge milestone to begin to have a device like this commercially available to regular patients. 1/
1
69
Aditi Qamra retweeted
Everyone wants to cure all diseases but nobody wants to do no hard ass biology experiments
Aditi Qamra retweeted
Introns have a hidden regulatory role! 🧬🎉
Delighted to share our latest paper showing that inefficiently spliced introns and spliceosomal proteins direct RNA methylation, engaging RNAi to silence retrotransposons and regulate gene expression
nature.com/articles/s41467-0…
🤖 Made with AI
Aditi Qamra retweeted
To be clear, not saying sc is a bad tool.
But 'predicting novel targets' means engaging with pathophysiology you're trying to reverse. Cell culture doesn't have pathophysiology.
The models aren't built for novel targets in complex disease. Good work, for a different question.
Its the first im seeing of experimental validation being treated at equal pedestal as drug design. Huge kudos to the team for baking it in their pipeline and then optimizing for efficiency rather than as an afterthought
Replying to @isaakfreeman
How did we achieve so fast end-to-end testing? Our proprietary Capable Core: We verticalized key steps of preclinical development. Our platform consists of 6 semi-autonomous modules, most of which we re-engineered to run 10–20x faster.
Drug design, ML infra, rapid synthesis, quality control, cell testing, and then mouse testing.
Our first modality at the 24h pace is binders & peptides--including complex modifications, cyclization, and noncanonical amino acids.
Mouse studies: For many of the biologically fast readouts, such as our short sleeper programs, we are able dose new drugs in placebo-controlled in vivo studies within that 24h period too and can read out early significant differences between drug candidates rapidly.
We achieved this through an in vivo facility in the lab, pre-approved protocols, and veterinarians & in vivo researchers on standby. This doesn't work for all indications: For Alzheimer's models the time-to-first-signal in vivo read-out is longer. For all drug candidates, before clinical testing we do standard chronic studies.
1
3
1,343
Aditi Qamra retweeted
Our recommendations include:
→ Transition to genome benchmarking
It is time to move beyond isolated small-variant metrics towards evaluating entire genomes against complete, diploid reference sequences to accurately evaluate and benchmark complex genetic variation.
Aditi Qamra retweeted
As an AI optimist, I do think AI will fundamentally transform biology and medicine. But after 25 years in academia and biotech and doing biology and quantitative biology at the highest levels, I think many AI companies encounter two very hard truths as tech companies have in the past.
First, drug development is constrained by regulatory requirements, clinical trial frameworks, and their incentive structures that determine what can be discovered, tested, and ultimately brought to patients. Better models alone do not solve those bottlenecks.
Second, AI is only as powerful as the questions it is asked. Biology is an extraordinarily difficult field because we still lack the right conceptual frameworks for understanding how living systems work. AI will accelerate discovery, but only if someone knows which problems matter, what data are informative, and how to distinguish mechanism from correlation.
In my experience, people who can do that are incredibly rare. Many areas of biology have only a handful of scientists with both deep biological intuition and the mindset needed to fully exploit AI. They know which data should exist but don’t, which experiments will change our understanding, and which questions are worth asking in the first place.
AI companies recruit elite computer scientists with extraordinary urgency. If they want to transform biology, they will need to recruit elite biologists with the same urgency. Otherwise, they’ll be limited by the quality of the biological questions those models are asked to solve.
I wish Anthropic well, especially since the history of drug development is a graveyard of tech companies trying to do drug discovery, mostly because tech companies just don’t get the complexity, uncertainty, revenue potential and timelines for biology. Anthropic does seem different since they’re much more science-oriented than the average tech company, so I hope it works.
Aditi Qamra retweeted
Claude Science is incredible. I gave it some sequencing data, and in 8 hours it did a full analysis, generated figures, wrote a paper, submitted it for publication, got rejected, revised and resubmitted, got rejected again, it is now applying for positions in industry
Aditi Qamra retweeted
Hope "AI Scientists" don't go the same trajectory as many bioinformatics tools. 10000 flavors. Impossible to know who is better for what purposes. Everyone benchmark maxxing. Users bewildered & confused. Hopefully they will all be equally useful rather than equally useless.
So friggin cool. I love the fact that this was achieved non-traditionally. Started out of a lab set up in an airbnb, scientists with lateral expertise came together, upskilled and achieved this vision - huge kudos 👏
We recently obtained the highest-resolution 3D images of the human brain ever taken from outside the skull. This is the first look.
Introducing Aleph, a research lab building brain interfaces for the telepathic future. (1/n)
47
If we are talking about pipe dreams re imaging then here is mine datatodrugs.substack.com/p/a…
20
Aditi Qamra retweeted
Shows very nicely why the current “virtual cell” efforts are just a waste of compute. People throwing data at models hoping that they learn principles without the proper context, rather than putting effort in to actually capture the underlying biochemistry/biology.
























